Nephroprotective Effects of the Dual GCGR / GLP ‐ 1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11915-11926
DOI: 10.1111/dom.71387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 01.10.2026. Verfasst von Alexander Hamilton und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gubra A/S, Hørsholm, Denmark. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Glucagon-Like Peptide-1 Receptor Agonists, Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Aims
Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function in chronic kidney disease (CKD), including diabetic kidney disease (DKD). This study aimed to characterize the effects of survodutide in a translational mouse model of advanced DKD, induced by adeno‐associated virus‐mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) diabetic db/db mice. Materials and Methods Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post‐UNx, db/db UNx‐ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks. Endpoints included blood/urine biochemistry, histological markers of glomerulosclerosis, tubular injury and inflammation, as well as quantitative 3D whole‐pancreas and whole‐kidney imaging.
Results
Compared to vehicle controls, survodutide reduced body weight, hyperglycemia, and HbA1c levels concurrent with improved hyperinsulinemia and β‐cell islet volume distribution. Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation. 3D whole‐kidney imaging revealed that survodutide significantly reduced kidney and glomerular hypertrophy while increasing glomerular density and improving glomerular sphericity. Survodutide reduced liver weight and plasma amino acid levels, including alanine, confirming hepatic glucagon receptor activation.
Conclusions
Survodutide markedly improved metabolic and renal outcomes in the db/db UNx‐ReninAAV mouse model of advanced DKD, supporting further investigation into therapeutic options of survodutide in chronic kidney diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gubra A/S, Hørsholm, Denmark.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
ORCID-Profile: Alexander Hamilton, Henrik H Hansen, Thomas Klein
Förderung
- Boehringer Ingelheim
Zitieren
APA
Hamilton, A., Thisted, L., Ougaard, M., Hahn, M., Andersen, K., Perens, J., Augustin, R., Bajrami, B., Rist, W., Christensen, M., Hansen, H. H., & Klein, T. (2026). Nephroprotective Effects of the Dual GCGR / GLP ‐ 1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease. Diabetes, Obesity and Metabolism, 28(12), 11915-11926. https://doi.org/10.1111/dom.71387
Vancouver
Hamilton A, Thisted L, Ougaard M, Hahn M, Andersen K, Perens J, et al. Nephroprotective Effects of the Dual GCGR / GLP ‐ 1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease. Diabetes, Obesity and Metabolism. 2026;28(12):11915-11926. doi:10.1111/dom.71387
BibTeX
@article{Hamilton2026,
author = {Hamilton, Alexander and Thisted, Louise and Ougaard, Maria and Hahn, Max and Andersen, Kasper and Perens, Johanna and Augustin, Robert and Bajrami, Besnik and Rist, Wolfgang and Christensen, Michael and Hansen, Henrik H and Klein, Thomas},
title = {Nephroprotective Effects of the Dual GCGR / GLP ‐ 1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11915--11926},
doi = {10.1111/dom.71387}
}
EUVIMED